Alliances
Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox.
Aldeyra Therapeutics has signed a collaboration research deal with Janssen Research & Development, a Johnson & Johnson company.
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy.
Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
Rumors of Nektar Therapeutics being up for sale may have been premature.
Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.
With the deal in hand, Roivant has stepped into the world of metabolic diseases.
Shares of Pieris have climbed more than 10 percent this morning after the company announced it inked a multi-program immuno-oncology collaboration with Seattle Genetics.
PRESS RELEASES